不同激素受体作为乳腺癌预后标志物的研究进展

乳腺癌是导致女性死亡的主要病因之一，因此现在对于相关标志物及治疗靶位点的研究非常重要。不同亚型乳腺癌其药物治疗反应及远期预后是不同的。例如三阴性乳腺癌雌激素受体-α（estrogen receptor-α，ER-α），孕激素受体（progesterone receptor，PR），人类表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）均为阴性，完全缺乏可用的生物标志物来评估预后，其治疗反应也较差。近年来体内外实验结果表明，孕激素受体膜组分1（progesterone receptor membrane component 1，PGRMC1）在乳腺癌的发生发展过程中起着重要作用。那么不同激素受体在乳腺癌发展及预后中的预测作用如何，PGRMC1是否有可能成为新型乳腺癌预后标志物?在本篇综述中，将针对这一系列问题进行阐述。

Different hormone receptors and their roles as prognostic markers in breast cancer

Breast cancer is one of the leading causes of death in women,and there is an urgent need for new biomarkers and therapeutic targets.The drug treatment response and long-term prognosis of various breast cancer subtypes are different. In cases like triple negative breast cancer estrogen receptor-α(ER-α), progesterone receptor(PR), and human epidermal growth factor receptor-2 (HER-2), there is a complete lack of available biomarkers for prognosis,and therapeutic response is poor. In recent years, in vitro and in vivo experiments have shown that progesterone receptor membrane component 1 (PGRMC1) plays an important role in the occurrence and development of breast cancer. So how do different hormone receptors predict the development and prognosis of breast cancer? Will PGRMC1 be a new potential prognostic marker for breast cancer in the future? We will review the results of related researches.